Bristol-Myers Squibb faces revenue declines but offers long-term potential via growth drugs. Read what BMY stock has to offer ...

Discover why Bristol-Myers Squibb's undervalued stock, strong cash flow, and 5% dividend yield make it an attractive buy ...

The FDA said risks linked to CAR-T cell therapies can be effectively communicated through existing labeling, including boxed ...

Cigna sued Bristol Myers Squibb on Tuesday, accusing the drugmaker of violating U.S. antitrust law by keeping generic ...

Bristol Myers Squibb to cut 68 jobs in Lawrenceville as part of a broader restructuring effort aiming to slash $2B in costs ...

Detailed price information for Bristol-Myers Squibb Company (BMY-N) from The Globe and Mail including charting and trades.

Bristol-Myers Squibb (NYSE:BMY) recently announced dividend declarations for common and preferred stock, potentially adding ...

FDA approved label changes for Breyanzi and Abecma, easing access by reducing monitoring rules and eliminating REMS safety ...

Bristol-Myers Squibb’s first quarter results reflected a blend of strong execution in its newer growth portfolio and ongoing ...

Princeton: Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has approved label updates for ...

This was the stock's third consecutive day of losses.

BioNTech and Bristol Myers Squibb have agreed to jointly develop and commercialize BioNTech’s BNT327 cancer-drug candidate in a deal potentially worth more than $11 billion to the German drugmaker.